Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor
Open accessAbstract
Mutations in von Hippel-Lindau tumor suppressor gene (VHL) underlie the VHL hereditary cancer syndrome and also occur in most sporadic clear cell renal cell cancers (CCRCC). Currently, the mechanism(s) by which VHL loss of function promotes tumor development in the kidney are not fully elucidated. Here, we show that VHL inactivation in precancerous lesions in kidneys from patients with VHL disease correlates with marked down-regulation of the intercellular adhesion molecule E-cadherin. Moreover, in VHL-defective cell lines (RCC4 and RCC10) derived from sporadic CCRCC, reexpression of VHL was found to restore E-cadherin expression. The product of the VHL gene has multiple reported functions, the best characterized of which is its role as the recognition component of an ubiquitin E3 ligase complex responsible for mediating oxygen-dependent destruction of hypoxia-inducible factor-α (HIF-α) subunits. We show that HIF activation is necessary and sufficient to suppress E-cadherin in renal cancer cells. Given the fundamental role of E-cadherin in controlling epithelial behavior, our findings give insight into how VHL inactivation/HIF activation may lead to kidney cancer and also indicate a mechanism by which reduced oxygenation could alter E-cadherin expression in other cancers and influence normal homeostasis in other epithelia. (Cancer Res 2006; 66(7): 3567-75)
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Loss of VHL in ccRCC downregulates E-cadherin in a HIF-dependent manner.
“Loss of VHL in ccRCC also downregulates E-cadherin in a HIF-dependent manner (Esteban et al., 2006).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Esteban et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,632 · see citing works
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · see citing works
Self-citationCano, A., Pérez‐Moreno, M., Rodrigo, I., Locascio, A., Blanco, M. J., Barrio, M. G. D., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,672 · see citing works
Batlle, E., Sancho, E., Francı́, C., Dominguez-Sola, D., Monfar, M., Baulida, J., & de Herreros, A. G. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,671 · see citing works
Multifunctional strands in tight junctions
Tsukita, S., Furuse, M., & Itoh, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067088 · Cited by 2,514 · see citing works
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · see citing works
The snail superfamily of zinc-finger transcription factors
Nieto, M. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm757 · Cited by 1,719 · see citing works
A causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A. T., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,419 · see citing works
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940 · see citing works
Self-citationMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865 · see citing works
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611 · see citing works
The cadherin-catenin adhesion system in signaling and cancer
Conacci‐Sorrell, M., Zhurinsky, J., & Ben‐Ze'ev, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15429 · Cited by 532 · see citing works
Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., Farese, R. V., Freeman, R. S., Carter, B. D., Kaelin, W. G., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.015 · Cited by 527 · see citing works
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483 · see citing works
Self-citationOhh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., & Iliopoulos, O. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80096-9 · Cited by 472 · see citing works
The cadherin-catenin adhesion system in signaling and cancer
Conacci‐Sorrell, M., Zhurinsky, J., & Ben‐Ze'ev, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215429 · Cited by 464 · see citing works
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · see citing works
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · see citing works
Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T., & Konishi, I. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63501-8 · Cited by 377 · see citing works
Sowter, H., Raval, R. R., Moore, J. W., Ratcliffe, P. J., & Harris, A. L. (2003) · PubMed · Cited by 374 · see citing works
Self-citationClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373 · see citing works
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
Hergovich, A., Lisztwan, J. H., Barry, R. E., Ballschmieter, P., & Krek, W. (2002) · Nature Cell Biology · doi:10.1038/ncb899 · Cited by 334 · see citing works
β-Catenin: A Pivot between Cell Adhesion and Wnt Signalling
Bienz, M. (2005) · Current Biology · doi:10.1016/j.cub.2004.12.058 · Cited by 310 · see citing works
Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors
Aprelikova, O. N., Chandramouli, G. V. R., Wood, M. J. A., Vasselli, J. R., Riss, J., Maranchie, J. K., Linehan, W. M., & Barrett, J. C. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20067 · Cited by 212 · see citing works
Tumor Metastasis: A New Twist on Epithelial–Mesenchymal Transitions
Vernon, A. E., & LaBonne, C. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.048 · Cited by 156 · see citing works
Nouwen, E. J., Dauwe, S. E. H., Biest, I. V. D., & Broe, M. E. D. (1993) · Kidney International · doi:10.1038/ki.1993.225 · Cited by 154 · see citing works
HIF-1 and hypoxic response: the plot thickens
Poellinger, L., & Johnson, R. S. (2003) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.12.006 · Cited by 149 · see citing works
Bishop, T., Lau, K. W., Epstein, A. C. R., Kim, S. K., Jiang, M., O’Rourke, D., Pugh, C. W., Gleadle, J., Taylor, M. S., Hodgkin, J., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020289 · Cited by 145 · see citing works
Davidowitz, E. J., Schoenfeld, A. R., & Burk, R. D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.865-874.2001 · Cited by 105 · see citing works
Esteban-Barragán, M. A., Ávila, P., Álvarez-Tejado, M., Gutiérrez, M. D. C., Garcı́a-Pardo, A., Sánchez‐Madrid, F., & Landázuri, M. O. (2002) · PubMed · Cited by 84 · see citing works
The von Hippel–Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis
Barry, R. E., & Krek, W. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.07.008 · Cited by 72 · see citing works
Villin--a marker of brush border differentiation and cellular origin in human renal cell carcinoma.
Gröne, H., Weber, K., Helmchen, U. M., & Osborn, M. (1986) · PubMed Central · Cited by 70 · see citing works
CpG methylation of promoter region inactivates E‐cadherin gene in renal cell carcinoma
Nojima, D., Nakajima, K., Li, L.-C., Franks, J., Ribeiro‐Filho, L. A., Ishii, N., & Dahiya, R. (2001) · Molecular Carcinogenesis · doi:10.1002/mc.1060 · Cited by 62 · see citing works
von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada, M., Suzuki, K., Kato, Y., Okuda, H., & Shuin, T. (2001) · PubMed · Cited by 56 · see citing works
Cao, Y., Karsten, U. R., Zerban, H., & Bannasch, P. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/pl00008210 · Cited by 49 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · see citing works
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · see citing works
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337 · see citing works
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · see citing works
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514 · see citing works
The cell-cell adhesion molecule E-cadherin
Roy, F. M. V., & Berx, G. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8281-1 · Cited by 1,330 · see citing works
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976 · see citing works
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941 · see citing works
Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., & Semenza, G. L. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.001 · Cited by 885 · see citing works
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806 · see citing works
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
Kaelin, W. G. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2502 · Cited by 729 · see citing works
Involvement of Members of the Cadherin Superfamily in CancerPreprint
Berx, G., & Roy, F. M. V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003129 · Cited by 711 · see citing works
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687 · see citing works
Beltran-Nebot, M., Puig, I., Peña, C., García, J. M., Álvarez, A. B., Peña, R., Bonilla, F., & de Herreros, A. G. (2008) · Genes & Development · doi:10.1101/gad.455708 · Cited by 677 · see citing works
Gravdal, K., HALVORSEN, O. J., Haukaas, S. A., & Akslen, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1263 · Cited by 562 · see citing works
Hypoxia-driven selection of the metastatic phenotype
Sullivan, R., & Graham, C. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9062-2 · Cited by 411 · see citing works
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M. D., & Jones, J. L. (2010) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 370 · see citing works
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
Finger, E. C., & Giaccia, A. J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9224-5 · Cited by 370 · see citing works
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363 · see citing works
Modulation of Shigella virulence in response to available oxygen in vivo
Marteyn, B., West, N. P., Browning, D. F., Cole, J. A., Shaw, J. G., Palm, F., Mounier, J., Prévost, M., Sansonetti, P. J., & Tang, C. M. (2010) · Nature · doi:10.1038/nature08970 · Cited by 323 · see citing works
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Vermeulen, P. B., Soetekouw, P. M. M. B., van Engeland, M., & A, A. P. D. B. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 317 · see citing works
Mikhaylova, O., Stratton, Y., Hall, D., Kellner, E., Ehmer, B., Drew, A. F., Gallo, C. A., Plas, D. R., Biesiada, J., Meller, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.019 · Cited by 313 · see citing works
Mitochondrial gateways to cancer
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 296 · see citing works
Chen, L., Xiao, Z., Meng, Y., Zhao, Y., Han, J., Su, G., Chen, B., & Dai, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.056 · Cited by 292 · see citing works
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Maxwell, P. H., & Eckardt, K. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.193 · Cited by 286 · see citing works
Self-citationHypoxia, gene expression, and metastasis
Chan, D. A., & Giaccia, A. J. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9063-1 · Cited by 276 · see citing works
Choosing the right cell line for renal cell cancer research
Brodaczewska, K. K., Szczylik, C. A., Fiedorowicz, M., Porta, C., & Czarnecka, A. M. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0565-8 · Cited by 264 · see citing works
The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia
Schietke, R. E., Warnecke, C., Wacker, I., Schödel, J., Mole, D. R., Câmpean, V., Amann, K., Goppelt‐Struebe, M., Behrens, J., Eckardt, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042424 · Cited by 253 · see citing works
VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail
Evans, A. J., Russell, R. C., Roche, O., Burry, T. N., Fish, J. E., Chow, V. W. K., Kim, W. Y., Saravanan, A., Maynard, M. A., Gervais, M. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00892-06 · Cited by 248 · see citing works
Cancer Stem Cells, Hypoxia and Metastasis
Hill, R. P., Marie-Egyptienne, D. T., & Hedley, D. W. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.12.002 · Cited by 240 · see citing works
E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells
Theys, J., Jutten, B., Habets, R., Paesmans, K., Groot, A. J., Lambin, P., Wouters, B. G., Lammering, G., & Vooijs, M. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.044 · Cited by 221 · see citing works
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Frew, I. J., & Moch, H. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040306 · Cited by 224 · see citing works
Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis
Saxena, K., Jolly, M. K., & Balamurugan, K. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100845 · Cited by 198 · see citing works
Li, W., Li, F., Zhang, X., Lin, H., & Xu, C. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 203 · see citing works
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195 · see citing works
Hypoxia-inducible factor signaling in the development of tissue fibrosis
Higgins, D. F., Kimura, K., Iwano, M., & Haase, V. H. (2008) · Cell Cycle · doi:10.4161/cc.7.9.5804 · Cited by 195 · see citing works
The VHL tumor suppressor: master regulator of HIF
Haase, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649394 · Cited by 175 · see citing works
The cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment
Filatova, A., Acker, T., & Garvalov, B. K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.10.008 · Cited by 166 · see citing works
Xue, D., Wang, H., Chen, Y., Shen, D., Lu, J., Wang, M., Zebibula, A., Xu, L., Wu, H., Li, G., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1072-5 · Cited by 163 · see citing works
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 161 · see citing works
Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies
Tanabe, S., Quader, S., Cabral, H., & Ono, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00904 · Cited by 161 · see citing works
Esteban, M. A., Harten, S. K., Tran, M. G. B., & Maxwell, P. H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020181 · Cited by 160 · see citing works
Self-citationThe VHL tumor suppressor and HIF: insights from genetic studies in mice
Kapitsinou, P. P., & Haase, V. H. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402313 · Cited by 151 · see citing works
Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells
Lee, S. H., Kim, J., Kim, W.-H., & Lee, Y. M. (2008) · Oncogene · doi:10.1038/onc.2008.377 · Cited by 150 · see citing works
Lei, J., Ma, J., Ma, Q., Li, X., Liu, H., Xu, Q., Duan, W., Sun, Q., Xu, J., Wu, Z., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-66 · Cited by 150 · see citing works
Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice
Albers, J., Rajski, M., Schönenberger, D., Harlander, S., Schraml, P., von Teichman, A., Georgiev, S., Wild, P. J., Moch, H., Krek, W., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202231 · Cited by 149 · see citing works
Mitotic spindle misorientation in cancer – out of alignment and into the fire
Pease, J. C., & Tirnauer, J. S. (2011) · Journal of Cell Science · doi:10.1242/jcs.081406 · Cited by 147 · see citing works
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141 · see citing works
The role of hypoxia-inducible factors in cancer
Maynard, M. A., & Ohh, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7082-2 · Cited by 138 · see citing works
Shin, H., Cho, K., Kim, D. W., Han, D. H., Khalmuratova, R., Kim, S., Jeon, S., Min, Y., Lee, C. H., Rhee, C., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1706oc · Cited by 135 · see citing works
The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α
Gort, E. H., van Haaften, G. W., Verlaan-Klink, I., Groot, A. J., Plasterk, R. H. A., Shvarts, A., Suijkerbuijk, K. P. M., van Laar, T., van der Wall, E., Raman, V., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210795 · Cited by 133 · see citing works
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 126 · see citing works
The role of hypoxia-inducible factor-2 in digestive system cancers
Zhao, J., Du, F., Shen, G., Zheng, F., & Xu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.565 · Cited by 122 · see citing works
Deletion of the von Hippel–Lindau gene in pancreatic β cells impairs glucose homeostasis in mice
Cantley, J., Selman, C., Shukla, D., Abramov, A. Y., Forstreuter, F., Esteban, M. A., Claret, M., Lingard, S. J., Clements, M., Harten, S. K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci26934 · Cited by 127 · see citing works
Self-citationMikami, S., Katsube, K., Oya, M., Ishida, M., Kosaka, T., Mizuno, R., Mukai, M., & Okada, Y. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.111 · Cited by 118 · see citing works
Harnessing the hypoxia-inducible factor in cancer and ischemic disease
Brahimi-Horn, M. C., & Pouysségur, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.013 · Cited by 114 · see citing works
Haase, V. H. (2009) · Kidney International · doi:10.1038/ki.2009.222 · Cited by 110 · see citing works
Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S. R., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-07 · Cited by 108 · see citing works
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis
Myszczyszyn, A., Czarnecka, A. M., Matak, D., Szymański, Ł., Lian, F., Kornakiewicz, A., Bartnik, E., Kukwa, W., Kiéda, C., & Szczylik, C. A. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9611-y · Cited by 103 · see citing works
Chen, F., Zhou, J., Li, Y., Zhao, Y. F., Yuan, J., Cao, Y., Wang, L., Zhang, Z., Zhang, B., Wang, C. C., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899727 · Cited by 103 · see citing works
Cadherin Switching and Bladder Cancer
Bryan, R. T., & Tselepis, C. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.04.016 · Cited by 105 · see citing works
The role of HIF prolyl hydroxylases in tumour growth
Jokilehto, T., & Jaakkola, P. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01030.x · Cited by 102 · see citing works
Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression
Meisel, C. T., Porcheri, C., & Mitsiadis, T. A. (2020) · Cells · doi:10.3390/cells9081879 · Cited by 101 · see citing works
Prolyl Hydroxylase Domain Inhibitors: A Route to HIF Activation and Neuroprotection
Harten, S. K., Ashcroft, M. A., & Maxwell, P. H. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2870 · Cited by 99 · see citing works
Self-citationEcology meets cancer biology: The cancer swamp promotes the lethal cancer phenotype
Amend, S. R., & Pienta, K. J. (2015) · Oncotarget · doi:10.18632/oncotarget.3430 · Cited by 95 · see citing works
Peruzzi, B., Athauda, G., & Bottaro, D. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606850103 · Cited by 95 · see citing works
Pantuck, A. J., An, J., Liu, H., & Rettig, M. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2211 · Cited by 95 · see citing works
Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL
Li, M., & Kim, W. Y. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01238.x · Cited by 94 · see citing works
A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Dayan, F., Mazure, N. M., Brahimi-Horn, M. C., & Pouysségur, J. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0006-3 · Cited by 93 · see citing works
Microenvironmental influences in melanoma progression
Lee, J. T., & Herlyn, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21204 · Cited by 94 · see citing works
Renal Tubular HIF-2α Expression Requires VHL Inactivation and Causes Fibrosis and Cysts
Schietke, R. E., Hackenbeck, T., Tran, M. G. B., Günther, R., Klanke, B., Warnecke, C., Knaup, K. X., Shukla, D., Rosenberger, C., Koesters, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031034 · Cited by 87 · see citing works
Self-citationHypoxia Induces Autophagic Cell Death through Hypoxia-Inducible Factor 1α in Microglia
Yang, Z., Zhao, T., Zou, Y., Zhang, J. H., & Feng, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096509 · Cited by 86 · see citing works
Gnemmi, V., Bouillez, A., Gaudelot, K., Hémon, B., Ringot-Destrez, B., Pottier, N., Glowacki, F., Villers, A. A., Vindrieux, D., Cauffiez, C., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.029 · Cited by 83 · see citing works
The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis
Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N., & Dubinett, S. M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0089-0 · Cited by 84 · see citing works
Pathophysiological Consequences of HIF Activation
Haase, V. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05030.x · Cited by 81 · see citing works
Tanaka, T., & Nangaku, M. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283328eed · Cited by 79 · see citing works
Harten, S. K., Shukla, D., Barod, R., Hergovich, A., Balda, M. S., Matter, K., Esteban, M. A., & Maxwell, P. H. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-06-0566 · Cited by 79 · see citing works
Self-citationAblation of the p16INK4a tumour suppressor reverses ageing phenotypes of klotho mice
Sato, S., Kawamata, Y., Takahashi, A., Imai, Y., Hanyu, A., Okuma, A., Takasugi, M., Yamakoshi, K., Sorimachi, H., Kanda, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8035 · Cited by 76 · see citing works
Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis
Stockmann, C., Kerdiles, Y. M., Nomaksteinsky, M., Weidemann, A., Takeda, N., Doedens, A. L., Torres‐Collado, A. X., Iruela‐Arispe, M. L., Nizet, V., & Johnson, R. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912766107 · Cited by 76 · see citing works
Kim, B., Cho, H., Chung, J., Conway, C. M., Ylaya, K., Kim, J., & Hewitt, S. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-185 · Cited by 74 · see citing works
The Metalloprotease Meprinβ Processes E-Cadherin and Weakens Intercellular Adhesion
Huguenin, M., Müller, E. J., Rösmann, S., Oneda, B., Ambort, D., Sterchi, E. E., & Lottaz, D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002153 · Cited by 74 · see citing works
Ubiquitin Pathway in VHL Cancer Syndrome
Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06442 · Cited by 72 · see citing works
Metastasis and stem cell pathways
Barnhart, B. C., & Simon, M. C. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9053-3 · Cited by 71 · see citing works
VHL Inactivation Induces HEF1 and Aurora Kinase A
Xu, J., Li, H., Wang, B., Xu, Y., Yang, J., Zhang, X., Harten, S. K., Shukla, D., Maxwell, P. H., Pei, D., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040345 · Cited by 71 · see citing works
Self-citationCRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma
Schokrpur, S., Hu, J., Moughon, D. L., Liu, P., Lin, L. C., Hermann, K. J., Mangul, S., Guan, W., Pellegrini, M. A., Xu, H., et al. (2016) · Scientific Reports · doi:10.1038/srep29032 · Cited by 67 · see citing works
Intricate relationship between cancer stemness, metastasis, and drug resistance
Dakal, T. C., Bhushan, R., Xu, C., Gadi, B. R., Cameotra, S. S., Yadav, V., Maciaczyk, J., Schmidt‐Wolf, I. G. H., Kumar, A., & Sharma, A. (2024) · MedComm · doi:10.1002/mco2.710 · Cited by 71 · see citing works
Multitasking by pVHL in tumour suppression
Frew, I. J., & Krek, W. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.10.001 · Cited by 68 · see citing works
Role of theVHL(von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor
Nyhan, M. J., O’Sullivan, G. C., & McKenna, S. L. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360472 · Cited by 66 · see citing works
Cancer as robust intrinsic state shaped by evolution: a key issues review
Yuan, R., Zhu, X., Wang, G., Li, S., & Ao, P. (2017) · Reports on Progress in Physics · doi:10.1088/1361-6633/aa538e · Cited by 62 · see citing works
Invasion and metastasis of renal cell carcinoma
Mikami, S., Oya, M., Mizuno, R., Kosaka, T., Katsube, K., & Okada, Y. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0064-6 · Cited by 66 · see citing works
Bulfoni, M., Turetta, M., Ben, F. D., Loreto, C. D., Beltrami, A. P., & Cesselli, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101775 · Cited by 65 · see citing works
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma
Kľučková, K., & Tennant, D. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2801-6 · Cited by 66 · see citing works
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 65 · see citing works
Kim, J., Rini, B. I., & Hansel, D. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_22 · Cited by 64 · see citing works
HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells
Khurana, A., Liu, P., Mellone, P., Lorenzon, L., Vincenzi, B., Datta, K., Yang, B., Linhardt, R. J., Lingle, W. L., CHIEN, J. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3059 · Cited by 61 · see citing works
c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade
Ebelt, N. D., Cantrell, M. A., & Berg, C. L. V. D. (2013) · Genes & Cancer · doi:10.1177/1947601913485413 · Cited by 62 · see citing works
Koop, E. A., van Laar, T., van Wichen, D. F., de Weger, R. A., van der Wall, E., & van Diest, P. J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-175 · Cited by 61 · see citing works
Barontini, M., & Dahia, P. L. M. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.01.002 · Cited by 61 · see citing works
The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
Tian, W., Wang, Y., Xu, Y., Guo, X., Wang, B., Sun, L., Liu, L., Cui, F., Zhuang, Q., Bao, X., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538157 · Cited by 59 · see citing works
Self-citationRegulation of vitamin metabolism by p53 and p63 in development and cancer
Zhou, H., & van Bokhoven, H. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12591 · Cited by 59 · see citing works
- Authors
- Esteban, M. A., Tran, M. G. B., Harten, S. K., Hill, P., Castellanos, M. C., Chandra, A., Raval, R., O'Brien, T. S., & Maxwell, P. H.
- Affiliations
- Imperial College London (GB)
- 3Servicio de Immunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain; and
- Guy's Hospital (GB)
- 4Henry Wellcome Building of Genomic Medicine, Oxford, United Kingdom
- 2Department of Urology, Guy's Hospital, London Bridge, London, United Kingdom;
- Venue
- Cancer Research
- Published
- 2006-04-01
- Volume
- 66
- Issue
- 7
- Pages
- 3567-3575
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2039412091
- Cited by
- 262
- References
- 37
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 7 · 2018: 10 · 2017: 5 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 17 · 2012: 19
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- European Commission
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- E-cadherin, von Hippel-Lindau tumor suppressor, hypoxia-inducible factor alpha, clear cell renal cell carcinoma, von Hippel-Lindau disease, cell-cell adhesion, epithelial cell adhesion, E3 ubiquitin ligase, tumor suppressor inactivation, oxygenation
- MeSH terms
- Adult, Carcinoma, Renal Cell, Cell Transformation, Neoplastic, Female, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Kidney Tubules, Male, Middle Aged, Precancerous Conditions, RNA, Messenger, Down-Regulation, Cadherins, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
